Search Results

UCB announced the first presentation of two-year data from the Phase 3 studies, BE MOBILE 1 and BE MOBILE 2, and the open-label extension, BE MOVING, evaluating BIMZELX, an interleukin -17A and IL-17F inhibitor, in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis, also known as radiographic axial spondyloarthritis.

Axial Therapeutics announced that A. Stewart Campbell, PhD, Chief Executive Officer, will participate in the following upcoming conferences.

Axial3D today announced that it is the first to receive FDA clearance for an automated, AI-driven, cloud-based segmentation platform for orthopedic trauma, orthopedic, maxillofacial, and cardiovascular applications.

Axial Therapeutics today announced completion of enrollment in the TAPESTRY Autism Study, the Phase 2b clinical trial of its lead product candidate, AB-2004, a first-in-class oral gut-targeted small molecule therapeutic designed to treat irritability associated with autism.